Incremental economic burden associated with exudative age-related macular degeneration: a population-based study

被引:29
|
作者
Kim, Siin [1 ]
Park, Sang Jun [2 ]
Byun, Seong Jun [2 ,3 ]
Park, Kyu Hyung [2 ]
Suh, Hae Sun [1 ]
机构
[1] Pusan Natl Univ, Coll Pharm, 2,Busandaehak Ro 63beon Gil, Busan, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, 82,Gumi Ro 173beon Gil, Seongnam Si, Gyeonggi Do, South Korea
[3] Sungkyunkwan Univ, Sch Pharm, 2066 Seobu Ro, Suwon, Gyeonggi Do, South Korea
基金
新加坡国家研究基金会;
关键词
Age-related macular degeneration; Cost of illness; Exudative AMD; Incremental cost; Macular degeneration; Models; econometric; Ranibizumab; Propensity score; HEALTH; PREVALENCE; COSTS;
D O I
10.1186/s12913-019-4666-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background The exudative age-related macular degeneration (AMD) causes considerable healthcare costs for patients and healthcare system, which are expected to grow as the population ages. The objective of this study was to assess the incremental economic burden of exudative AMD by comparing total healthcare costs between the exudative AMD group and non-AMD group to understand economic burden related to exudative AMD. Methods This retrospective cohort study used the National Health Insurance Service database including the entire Korean population. Exudative AMD group included individuals with at least one claim for ranibizumab and one claim using the registration code for exudative AMD (V201). Non-AMD group was defined as individuals without any claims regarding the diagnostic code of H35.3 or ranibizumab. The exudative AMD group and non-AMD group were matched using a propensity-score model. Incremental healthcare resource utilization and healthcare costs were measured during a one-year follow-up by employing econometric models: ordinary least squares (OLS) with log transformation and heteroscedastic retransformation; and generalized linear model (GLM) with a log link function and gamma distribution. Results A total of 7119 exudative AMD patients were matched to 7119 non-AMD patients. The number of outpatient visits was higher in the exudative AMD group (P-value < 0.0001), while the length of hospitalization was shorter in exudative AMD group (P-value < 0.0001). Exudative AMD patients had total costs 2.13 times (95%CI, 2.08-2.17) greater than non-AMD group using OLS, and total costs 4.06 times (95%CI, 3.82-4.31) greater than non-AMD group using GLM. Annual incremental total costs were estimated as $5519 (OLS) and $3699 (GLM). Conclusions Exudative AMD was associated with significantly increased healthcare costs compared to the non-AMD group. Attention is needed to manage the socioeconomic burden of exudative AMD.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study
    José M. Ruiz-Moreno
    Luís Arias
    Maximino J. Abraldes
    Javier Montero
    Patricia Udaondo
    International Ophthalmology, 2021, 41 : 3427 - 3436
  • [42] TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
    Forooghian, Farzin
    Cukras, Catherine
    Meyerle, Catherine B.
    Chew, Emily Y.
    Wong, Wai T.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (06): : 723 - 731
  • [43] Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept
    Chikako Hara
    Taku Wakabayashi
    Yoko Fukushima
    Kaori Sayanagi
    Ryo Kawasaki
    Shigeru Sato
    Hirokazu Sakaguchi
    Kohji Nishida
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257 : 2559 - 2569
  • [44] Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration
    Real, Juan P.
    Luna, Jose D.
    Urrets-Zavalia, Julio A.
    De Santis, Mariana O.
    Palma, Santiago D.
    Granero, Gladys E.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2013, 23 (06) : 857 - 864
  • [45] Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept
    Hara, Chikako
    Wakabayashi, Taku
    Fukushima, Yoko
    Sayanagi, Kaori
    Kawasaki, Ryo
    Sato, Shigeru
    Sakaguchi, Hirokazu
    Nishida, Kohji
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 257 (11) : 2559 - 2569
  • [46] A systematic review on the effect of bevacizumab in exudative age-related macular degeneration
    Schmucker, Christine
    Antes, Gerd
    Lelgemann, Monika
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (03) : 451 - 452
  • [47] Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration
    Gamulescu M.-A.
    Radeck V.
    Lustinger B.
    Bianca Fink B.
    Helbig H.
    International Ophthalmology, 2010, 30 (3) : 261 - 266
  • [48] Visual acuity loss associated with excessive "dry macula" in exudative age-related macular degeneration
    Takahashi, Hidenori
    Inoue, Yuji
    Tan, Xue
    Inoda, Satoru
    Sakamoto, Shinichi
    Arai, Yusuke
    Yanagi, Yasuo
    Fujino, Yujiro
    Kawashima, Hidetoshi
    CLINICAL OPHTHALMOLOGY, 2018, 12 : 369 - 375
  • [49] Complications Associated with Worse Visual Outcomes in Patients with Exudative Neovascular Age-Related Macular Degeneration
    Barresi, Costanza
    Borrelli, Enrico
    Fantaguzzi, Federico
    Grosso, Domenico
    Sacconi, Riccardo
    Bandello, Francesco
    Querques, Giuseppe
    OPHTHALMOLOGICA, 2021, 244 (06) : 512 - 522
  • [50] The impact of glucosamine on age-related macular degeneration in patients: A nationwide, population-based cohort study
    Feng, Kathy Ming
    Chien, Wu-Chien
    Chen, Jiann-Torng
    Chen, Yi-Hao
    Chung, Chi-Hsiang
    Sun, Chien-An
    Chen, Ching-Long
    PLOS ONE, 2021, 16 (05):